STUDY OF ANTI-PEPTIDYL ARGININE DEIMINASE 4 AUTO ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS AND THEIR CORRELATION WITH ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN TELANGANA POPULATION

RAJKUMAR GUNDU; LAKSHMI PRABHA S; PONNUDHALI D

doi:10.22159/ajpcr.2025v18i7.54714

Authors

RAJKUMAR GUNDU Department of Biochemistry, Vinayaka Mission’s Medical College and Hospitals, Vinayaka Mission’s Research Foundation (Deemed to be University), Puducherry, India https://orcid.org/0009-0004-0472-4118
LAKSHMI PRABHA S Department of Biochemistry, Vinayaka Mission’s Kriupananda Variyar Medical College and Hospital, Salem, Tamil Nadu, India
PONNUDHALI D Department of Biochemistry, Vinayaka Mission’s Kriupananda Variyar Medical College and Hospital, Salem, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ajpcr.2025v18i7.54714

Keywords:

Rheumatoid arthritis, Anti Peptidyl arginine deiminase auto antibodies, Disease activity score 28, Anti-cyclic citrullinated peptide

Abstract

Objectives: This study aimed to evaluate the role of anti-peptidyl arginine deiminase 4 (PADI4) autoantibodies in the early diagnosis of rheumatoid arthritis (RA) and their association with Disease Activity Score 28 (DAS28) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.

Methods: A case–control study involving 196 subjects, 98 patients of confirmed RA patients and 98 healthy controls matched in age and sex, was carried out at Rheumatology department of Chalmeda Anand Rao Institute of Medical Sciences (CAIMS), hospital. Detailed history is taken. Patients were included after following the inclusion and exclusion criteria, getting informed consent from patients, and approved by the institutional ethical committee of CAIMS. Appropriate statistical analysis will be done after collecting data. Statistical Package for the Social Sciences version 25 was used for further statistical analysis. p<0.05 was considered as statistically significant, DAS28, rheumatoid factor (RF), Erythrocyte sedimentation rate, anti- CCP, antibodies, and anti-PADI4 antibodies were measured in RA patients and controls BY ELIAS sandwich method.

Results: Anti-PADI4 and anti-CCP antibody levels were significantly elevated in RA patients (p<0.001). Anti-PADI4 showed 68% sensitivity and 98% specificity, whereas anti-CCP had 84% sensitivity and 98% specificity. Combined testing increased diagnostic sensitivity to 90%. Anti-PADI4 levels showed positive correlations with DAS28 (r=0.54, p=0.006), anti-CCP (r=0.79, p<0.00001), and RF (r=0.62, p=0.0001). RA patients positive for anti- PADI4 had significantly higher DAS28 scores, RF, and anti-CCP levels than those negative for anti-PADI4. Anti-PADI4 also identified some anti-CCP-negative RA cases.

Conclusion: Serum anti-PADI4 Auto antibodies give an important diagnostic value with correlation with anti-CCP antibodies and DAS28

Downloads

Download data is not yet available.

References

Jyothirmayi P, Bharathi A, Sekhara Reddy DR. Formulation and evaluation of modified pulsatile capsule for chronopharmacotherapy of rheumatoid arthritic pain. Int J App Pharm. 2024;16(2):329-36. doi: 10.22159/ijap.2024v16i2.49073

Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037-47. PMID 16190501

Eagger K, Feist E, Bumester GR. The serological diagnosis of rheumatoid arthritis: Antibodies to citrullinated antigens. Dtsch Ärztebl Int. 2009;106(10):159-63.

Gyorgy B, Tóth E, Tarcsa E, Falus A, Buzás EI. Citrullination: A posttranslational modification in health and disease. Int J Bioche Cell Biol. 2006;38(10):1662-77.

Koushik S, Joshi N, Nagaraju S, Mahmood S, Mudeenahelly K, Padmavathy R, et al. PAD4: Pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. Experts Opin Ther Targets. 2017;3;21(4):433-47.

Anzilotti C, Pratesi F, Tommasi C, Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev. 2010;9(3):158-60. doi: 10.1016/j.autrev.2009.06.002, PMID 19540364

Anuradha N, Seeralaboopathy K, Harinisakthi S, Shenbhaga Praveen N, Sakthi SJ, Chandra Sekar NV, et al. Clinical significance of combined anti-cyclic citrullinated peptide antibody and rheumatoid factor assays in rheumatoid arthritis diagnosis. Int J Curr Pharm Rev Res. 2025;17(3):542-8.

Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with

and disease severity in rheumatoid arthritis. Arthritis Rheum. 2008;58(7):1958-67. doi: 10.1002/art.23596, PMID 18576335

Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003;34(4):395-402. doi: 10.1038/ng1206, PMID 12833157

Ikari K, Kuwahara M, Nakamura T, Momohara S, Hara M, Yamanaka H, et al. Association between PADI4 and rheumatoid arthritis: A replication study. Arthritis Rheum. 2005;52(10):3054-7. doi: 10.1002/art.21309, PMID 16200584

Iwamoto T, Ikari K, Nakamura T, Kuwahara M, Toyama Y, Tomatsu T, et al. Association between PADI4 and rheumatoid arthritis: A meta-analysis. Rheumatol (Oxford). 2006;45(7):804-7. doi: 10.1093/ rheumatology/kel023, PMID 16449362

Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: Association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77(6):1044-60. doi: 10.1086/498651, PMID 16380915

Zhao J, Zhao Y, He J, Jia R, Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol. 2008;35(6):969-74. PMID 18398945

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. doi: 10.1002/art.1780310302, PMID 3358796

Kolfenbach JR, Deane KD, Derber LA, O’Donnell CI, Gilliland WR, Edison JD, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633-9. doi: 10.1002/art.27570, PMID 20496417

Rantapää-Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-9. doi: 10.1002/art.11223, PMID 14558078

Nielen MM, Van Schaardenburg D, Reesink HW, Van De Stadt RJ, Van Der Horst-Bruinsma IE, De Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-6. doi: 10.1002/art.20018, PMID 14872479

Majka DS, Deane KD, Parrish LA, Lazar AA, Barón AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008;67(6):801-7. doi: 10.1136/ ard.2007.076679, PMID 17974596

Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004;6(4):R303-8. doi: 10.1186/ar1187, PMID 15225365

Van Gaalen FA, Linn-Rasker SP, Van Venrooij WJ, De Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum. 2004;50(3):709-15. doi: 10.1002/art.20044

Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol. 2005;34(3):212-5. doi: 10.1080/03009740510026346-1, PMID 16134727

Roth EB, Stenberg P, Book C, Sjöberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis--new pathways to epitope spreading. Clin Exp Rheumatol. 2006;24(1):12-8. PMID 16539813

Onder B, Kurtaran B, Selcuk B, Akova M. Anti-CCP antibodies in rheumatoid arthritis: Relationship with disease activity and severity. Rheumatol Int. 2009;29(1):75-80.

Auger I, Martin M, Balandraud N, Roudier J. Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen. Arthritis Rheum. 2010;62(1):126-31. doi: 10.1002/art.27230, PMID 20039406

Halvorsen EH, Pollmann S, Gilboe IM, Van Der Heijde D, Landewé R, Ødegård S, et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis. 2008;67(3):414-7. doi: 10.1136/ard.2007.080267, PMID 18006540

Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, Van Der Heijde D, Kvien TK, et al. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis. 2009;68(2):249-52. doi: 10.1136/ ard.2008.094490, PMID 18723564

Bozdag M, Dreker T, Henry C, Tosco P, Vallaro M, Fruttero R, et al. Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. Bioorg Med Chem Lett. 2013;23(3):715-9. doi: 10.1016/j. bmcl.2012.11.102, PMID 23265898

Maulana Kamri A, Nur Azizah R, Avista V. Effectiveness and side effects of using methotrexate and adalimumab in the treatment of rheumatoid arthritis patients. Int J App Pharm. 2023;15(2):117-22. doi: 10.22159/ijap.2023v15i2.46158